FDA promotes mandatory listing of dietary supplements and strengthens market traceability supervision

The US Congress advances the Dietary Supplement Listing Act in 2026, aiming to transform the decades‑old post‑market supervision model. All dietary supplements sold within the US shall complete mandatory FDA product listing registrationDemocrats.

The US Congress advances the Dietary Supplement Listing Act in 2026, aiming to transform the decades‑old post‑market supervision model. All dietary supplements sold within the US shall complete mandatory FDA product listing registrationDemocrats. Enterprises are required to submit full documentation including product name, complete ingredient list, electronic label copies, allergen statements and structure‑function claims to obtain a unique listing ID. Products without valid registration will be banned from circulation.

Once finalized, FDA will build a publicly‑searchable product database to help regulators locate non‑compliant goods and improve recall efficiency. Overseas health‑product manufacturers exporting to the US shall make preparations in advance, cooperate with US importers for information submission, and consolidate ingredient and label documents to avoid detention or delisting risks. The bill is under congressional review; its official effective date is yet to be announced。